Business Context and Reporting Period
Company: Repligen Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 1996
Business Overview: Repligen is a biotechnology company focused on developing therapies for chronic and acute inflammation and immunosuppression, as well as enabling technologies for drug discovery. Following a major restructuring in fiscal 1996, the company significantly downsized its workforce, terminated several research programs, and closed its Cambridge facility, relocating operations to Needham, Massachusetts.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 1996 | Six Months Ended Sep 30, 1996 | Six Months Ended Sep 30, 1995 |
|---|---|---|---|
| Total Revenues | $981,370 | $1,821,624 | $7,855,434 |
| Net Income (Loss) | $258,168 | $(210,846) | $(3,572,840) |
| EPS (Basic) | $0.02 | $(0.01) | $(0.23) |
| Cash and Cash Equivalents | $3,295,855 (Sep 30, 1996) | N/A | |
| Working Capital | $3,758,062 (Sep 30, 1996) | N/A | |
| Net Cash Used in Operating Activities | N/A | $(3,545,847) | $(2,752,995) |
Liquidity: Total cash, cash equivalents, and marketable securities stood at approximately $3.4 million as of September 30, 1996, down from $7.2 million at the end of the prior fiscal year. The company reported no long-term debt on the balance sheet.
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased approximately 80% for the three-month period and 77% for the six-month period compared to the prior year. This was primarily driven by the loss of significant research and development revenues from Eli Lilly and Company and Repligen Clinical Partners, L.P.
- Expense Reduction: Total expenses decreased 88% for the quarter and 82% year-to-date. This reduction reflects the fiscal 1996 restructuring, including a substantial reduction in headcount and the discontinuation of contract manufacturing activities.
- Profitability Shift: The company reported a net profit of $258,168 for the quarter ended September 30, 1996, compared to a net loss of $934,220 in the same period of the prior year. However, the six-month period ended September 30, 1996, still resulted in a net loss of $210,846, though significantly improved from the $3.57 million loss in the prior year.
- One-Time Gains: "Other" revenues increased due to one-time sales of equipment and non-investment securities totaling approximately $505,000.
Guidance, Outlook, and Risks
Management Commentary: Management believes the company has sufficient cash equivalents and marketable securities to satisfy working capital and capital expenditure requirements for the next twelve months. Future expansion of research or product development is dependent on increased product sales, future financing, or new partnerships.
Risks and Contingencies:
- Liquidity Risk: While current funds are deemed sufficient for 12 months, there is no assurance that additional financing will be available on favorable terms if needed.
- Operational Risk: Future results depend on the ability to meet working capital needs, implement growth strategies, and respond to rapidly changing technologies.
- Restructuring Settlements: The company settled facility and equipment lease obligations in the first quarter of fiscal 1997, resulting in significant cash outflows ($3.3 million total) which impacted operating cash flow.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $3.4 million cash position given the net cash used in operating activities of $3.5 million over the last six months.
- Revenue Concentration: Assess the impact of the loss of Eli Lilly and Repligen Clinical Partners revenues and the progress of new contract research programs.
- Restructuring Costs: Confirm that all accrued restructuring liabilities (severance, lease settlements) have been fully paid or adequately reserved.
- Product Pipeline: Evaluate the status of the Protein A product line and the development of new therapies for inflammation and immunosuppression.
- Stock Option Plan: Review the implications of the amended 1992 Stock Option Plan approved by shareholders in September 1996 regarding future dilution.